Jaguar Health (NASDAQ:JAGX) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Jaguar Health (NASDAQ:JAGXFree Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Jaguar Health Trading Down 16.0 %

Jaguar Health stock opened at $0.09 on Friday. The company has a debt-to-equity ratio of 6.33, a current ratio of 2.00 and a quick ratio of 1.34. Jaguar Health has a fifty-two week low of $0.05 and a fifty-two week high of $1.22. The firm has a fifty day moving average price of $0.08 and a two-hundred day moving average price of $0.18.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in JAGX. Renaissance Technologies LLC acquired a new position in shares of Jaguar Health during the first quarter valued at about $1,079,000. Millennium Management LLC grew its stake in Jaguar Health by 152.3% during the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company’s stock worth $157,000 after buying an additional 321,795 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Jaguar Health by 507.3% during the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock worth $120,000 after buying an additional 141,796 shares during the last quarter. Vanguard Group Inc. grew its stake in Jaguar Health by 141.7% during the third quarter. Vanguard Group Inc. now owns 192,335 shares of the biotechnology company’s stock worth $50,000 after buying an additional 112,770 shares during the last quarter. Finally, Virtu Financial LLC grew its stake in Jaguar Health by 76.1% during the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock worth $162,000 after buying an additional 99,073 shares during the last quarter. Institutional investors and hedge funds own 12.04% of the company’s stock.

Jaguar Health Company Profile

(Get Free Report)

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Read More

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.